ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0088

Evaluation of Patient Characteristics and Clinical Outcomes Among SARS‑CoV‑2‑Diagnosed Patients with and Without RA or PsA Treated with Systemic Therapies: A Retrospective Cohort Study Using US Optum® COVID-19 Electronic Health Record Data

Jeffrey Curtis1, Xiaofeng Zhou2, Jinoos Yazdany3, Philip Robinson4, Yan Chen2, Ann Madsen2, Jamie Geier2 and Birgitta Benda2, 1Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 2Pfizer Inc, New York, NY, 3University of California San Francisco, San Francisco, CA, 4Faculty of Medicine, The University of Queensland, Herston, Australia

Meeting: ACR Convergence 2021

Keywords: Infection, Psoriatic arthritis, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Patients with chronic rheumatic diseases are considered to be at increased risk for some infections, with prescribed immunomodulatory (IM) therapies increasing this risk further. It is unclear if patients with RA or PsA receiving IM therapies are at increased risk for SARS-CoV-2 infection, and if they experience more severe COVID-19 clinical outcomes compared with the general population. We describe the characteristics and COVID-19 clinical outcomes in this patient population.

Methods: This descriptive retrospective cohort study (a post-approval safety study of tofacitinib [approved for RA, PsA, and ulcerative colitis (UC) at the time of the study] in the context of the COVID-19 pandemic) used data from the US Optum® deidentified COVID-19 electronic health record dataset (2007–2020). Adults with a COVID-19 diagnosis (≥ 1 diagnosis code or positive SARS-CoV-2 laboratory test [including PCR, antibody, or antigen]) were stratified into 3 cohorts: patients with RA or PsA and evidence of treatment with IM therapy in the 2 yrs prior to COVID-19 diagnosis (RA and PsA cohorts); and patients without a diagnosis of RA, PsA, or UC and no record of IM therapy in the 2 yrs prior to COVID-19 diagnosis (comparator cohort). Baseline (SARS-CoV-2 diagnosis date) demographics, comorbidities, and IM therapy class were evaluated. The incidence proportions (IPs; with 95% confidence intervals) of primary endpoints (hospitalization and intensive care unit [ICU] admission) and COVID-19 clinical manifestations/outcomes of interest were calculated. Logistic regression was used in exploratory analyses to estimate the risk of endpoints, adjusting for demographics (age, sex, race, region), and demographics plus comorbidities.

Results: As of December 09, 2020, there were 2,306 patients in the RA cohort, 421 patients in the PsA cohort, and 311,563 patients in the comparator cohort. Compared with the comparator cohort, patients with RA and PsA were older and had a higher prevalence of baseline comorbidities (Table). Crude IP of hospitalization due to COVID-19 was higher in the RA cohort compared with the PsA and comparator cohorts (Table). ICU admission (conditional on hospitalization) was similar in the RA and comparator cohorts. Adjusting for demographics, COVID-19 patients with RA had an increased risk of hospitalization and in‑hospital death, compared with the comparator cohort (Figure 1). The increased risk was also observed when adjusted for demographics plus comorbidities. Risk of hospitalization was lower in COVID-19 patients with RA receiving TNF inhibitors (TNFi) vs non-TNFi biologics and the comparator cohort (Figure 2). In the RA cohort, risk of hospitalization due to COVID-19 was similar between patients receiving tofacitinib and the comparator cohort (Figure 2).

Conclusion: Compared with the comparator cohort, patients with RA were at higher risk of more severe or critical COVID-19; except for non-TNFi biologics, immunosuppressive therapies such as TNFi did not further increase the risk.

Acknowledgments: Study sponsored by Pfizer Inc. Medical writing support was provided by H Findlow, CMC Connect, funded by Pfizer Inc.


Disclosures: J. Curtis, AbbVie, 2, Amgen, 2, 5, Bristol-Myers Squibb, 2, Janssen, 2, Eli Lilly, 2, Myriad, 2, Pfizer Inc, 2, 5, Roche/Genentech, 2, UCB, 2, CorEvitas, 2, 5, Crescendo Bio, 5; X. Zhou, Pfizer Inc, 3, 11; J. Yazdany, Pfizer, 2, Astra Zeneca, 5, Eli Lilly, 2, University of California, San Francisco, 3; P. Robinson, Abbvie, 5, UCB Pharma, 5, Novartis, 5, 6, Gilead, 6, Eli Lilly, 6, Pfizer Inc, 5, 6, Janssen, 5, 6, Roche, 6, 12, The University of Queensland, 3; Y. Chen, Pfizer Inc, 3, 11; A. Madsen, Pfizer Inc, 3, 11; J. Geier, Pfizer Inc, 3, 11; B. Benda, Pfizer Inc, 3, 11.

To cite this abstract in AMA style:

Curtis J, Zhou X, Yazdany J, Robinson P, Chen Y, Madsen A, Geier J, Benda B. Evaluation of Patient Characteristics and Clinical Outcomes Among SARS‑CoV‑2‑Diagnosed Patients with and Without RA or PsA Treated with Systemic Therapies: A Retrospective Cohort Study Using US Optum® COVID-19 Electronic Health Record Data [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/evaluation-of-patient-characteristics-and-clinical-outcomes-among-sars%e2%80%91cov%e2%80%912%e2%80%91diagnosed-patients-with-and-without-ra-or-psa-treated-with-systemic-therapies-a-retrospective-coho/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-patient-characteristics-and-clinical-outcomes-among-sars%e2%80%91cov%e2%80%912%e2%80%91diagnosed-patients-with-and-without-ra-or-psa-treated-with-systemic-therapies-a-retrospective-coho/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology